Teva Pharmaceutical Industries Limited and Viatris Inc.: SG&A Spending Patterns Compared

SG&A Spending Trends: Teva vs. Viatris

In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial. Over the past decade, Teva Pharmaceutical Industries Limited and Viatris Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Teva's SG&A expenses decreased by approximately 31%, reflecting a strategic shift towards cost efficiency. In contrast, Viatris saw a significant increase of around 210% in the same period, indicating aggressive expansion and investment in operational capabilities.

Key Insights

• Teva's Cost Efficiency: Teva's SG&A expenses peaked in 2016 and have since declined, suggesting a focus on streamlining operations.
• Viatris' Growth Strategy: Viatris' expenses surged, especially post-2020, highlighting its commitment to growth and market penetration.

These trends offer a glimpse into the strategic priorities of these pharmaceutical giants, providing valuable insights for investors and industry analysts.